EP1121126A1 - Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede - Google Patents

Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede

Info

Publication number
EP1121126A1
EP1121126A1 EP99948923A EP99948923A EP1121126A1 EP 1121126 A1 EP1121126 A1 EP 1121126A1 EP 99948923 A EP99948923 A EP 99948923A EP 99948923 A EP99948923 A EP 99948923A EP 1121126 A1 EP1121126 A1 EP 1121126A1
Authority
EP
European Patent Office
Prior art keywords
nicotine
pharmaceutically acceptable
medical device
acceptable salt
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP99948923A
Other languages
German (de)
English (en)
Inventor
Reinhold Meconi
Volker Siemund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1121126A1 publication Critical patent/EP1121126A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the invention is directed to a method and an apparatus for treating schizophrenia.
  • Schizophrenia is a mental illness that was first developed by E. Kraepelin by summarizing individual characteristics, e.g. B. paranoid and catatons
  • Condition pictures has been described as a disease.
  • the main deficit underlying this condition is a division of mental functions.
  • schizophrenia has different faces and the different symptoms appear in different forms and combinations. Typical forms are paranoid-hallucinatory schizophrenia, catatonic schizophrenia, schizophrenia simplex and Hebephrenia.
  • Symptoms of schizophrenia include disorders of the course of thought, content-related thinking disorders, illusions, so-called "ego disorders", disorders of the emotional world (affect disorders) as well as disorders of movement and drive.
  • the schizoaffective psychoses occupy a middle position between the schizophrenia and the cyclothymia.
  • the basic symptoms include disturbances in thinking (embarrassment, termination of thoughts, changes in the chain of thoughts), disturbances in affectivity (indifference, hypersensitivity, irritability, loss of contact, ambivalence of feelings) and disturbances in one's own experience (depersonalization, experiences of alienation and influence, cleavage of personality ).
  • the accessory symptoms include hallucinations (acoustic, visual, olfactory and taste hallucinations), delusion (persecution, poisoning, sexual delusion, etc.), motor and drive disorders (immobility, mutism, drive inhibition) and language changes (mannerisms , playful expressions, word formations, constant repetitions).
  • hallucinations acoustic, visual, olfactory and taste hallucinations
  • delusion persecution, poisoning, sexual delusion, etc.
  • motor and drive disorders immobility, mutism, drive inhibition
  • language changes mannerisms , playful expressions, word formations, constant repetitions.
  • Schizophrenia is considered to be incurable, i.e. causal treatment is considered - as is the case with many organic diseases, such as B. Diabetes - as not possible.
  • a pal ative treatment is possible, so that in a majority of the patients the symptoms can be suppressed at least so much that hospitalization is unnecessary or the patient's regular everyday life is facilitated.
  • the invention is therefore based on the object of providing a method and a medicament which make it possible to treat the symptoms of patients with schizophrenia and which is suitable for use in addition or as part of psychotherapy and / or sociotherapy, as a result of which the Disadvantages of treatment with neuroleptics or other psychologically active substances can be reduced or avoided. Even the weaknesses of the intermittent nicotine intake by means of nicotine chewing gum and the disadvantages of the mucous membrane irritant effect of nicotine when administered orally are to be avoided.
  • the object is achieved by a method and a medicament which is used for the continuous administration of nicotine, preferably to and through the skin over a longer period, for example over a 16 or 24 hour period and preferably over a period of several days, e.g. B. 3-day period is suitable.
  • TTS transdermal therapeutic systems
  • EP 400 078 EP 427 741 and EP 708 627.
  • TTS transdermal therapeutic systems
  • the active ingredient nicotine via a 16th hours (EP 400 078), or a 24-hour period.
  • TTS can be produced which also contain the active ingredient nicotine over a longer period of time, e.g. B. can give 3 days.
  • the active substance content and the thickness of the matrix containing the active substance and the skin contact surface of the TTS types used have to be adapted for the desired application time.
  • the active ingredient nicotine means the naturally occurring (-) - nicotine. Nicotine has two nitrogen atoms.
  • the pharmaceutically acceptable salts of nicotine include the mono salts of saiicylic acid, phenylpropionic acid or dodecanoic acid. Nicotine monoacetate, nicotine sulfate, nicotine hydrochloride, nicotine valerate, nicotine pivalate, nicotine lactate etc. are also preferred as active ingredients. Of course, this list cannot be exhaustive.
  • the mixture of nicotine (as a free base) with a nicotine seed is also suitable as an active ingredient. This can be the case with a longer planned application period. Free nicotine base permeates through the skin faster than many of the nicotine salts. After a certain time, this leads to exhaustion of the nicotine in the active substance reservoir of the TTS. The nicotine salt content in the drug reservoir slows down when the free base in the drug reservoir is exhausted. The salt then plays a greater role in nicotine delivery and maintenance of nicotine blood plasma levels later in the application of the TTS.
  • the constructive elements of the TTS are a backing layer, a layer containing the active ingredient and a layer that causes adhesion to the skin.
  • the TTS can also be constructed in such a way that the functions "layer containing active ingredient” and "layer causing adhesion to the skin” are realized in a single layer.
  • the TTS can have a control membrane, which is between the
  • the control membrane has the function of controlling the rate of release of the active ingredient from the TTS.
  • the active ingredient can also be present in microencapsulated form in the active ingredient-containing layer.
  • the capsule material enveloping the active substance would then take on this function which controls the release.
  • the backing layer is impermeable to the active substance and preferably impermeable to light and oxygen in order to avoid chemical decomposition of the active substance by substances penetrating from outside.
  • the TTS can also have separate drug reservoirs in a surrounding matrix.
  • the TTS is able to reach a nicotine blood plasma level above 2 ng / ml within a period of 4 hours after application.
  • a TTS is suitable to achieve an essentially constant nicotine biutplasma level between 2 and 20 ng / ml after a period of 4 hours after application.
  • a TTS is preferred which is suitable for achieving a substantially constant nicotine blood plasma level of between 2 and 10 ng / ml after a period of 4 hours after application.
  • the method for treating schizophrenia is to stick a TTS according to the invention on the patient's skin and after the remove the intended duration of use.
  • This application time for a single TTS can be 16 hours or 24 hours.
  • Multi-day TTS, e.g. B. are suitable for a three-day application.
  • Long-term therapy is meaningful, ie an application of such nicotine TTS according to the invention, possibly for months or years.
  • This type of long-term drug therapy using transdermal nicotine can be used simultaneously with psychotherapy and / or sociotherapy and / or drug therapy, especially with drugs that specifically block the receptors for dopamine (olanzapine, risperidone, etc.).

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de nicotine ou d'un sel de nicotine ou d'un mélange de nicotine et de sel de nicotine, administrés par voie transdermique, pour le traitement de la schizophrénie. Elle concerne également un procédé et un dispositif médical correspondant.
EP99948923A 1998-10-16 1999-10-02 Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede Ceased EP1121126A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19847715 1998-10-16
DE19847715A DE19847715A1 (de) 1998-10-16 1998-10-16 Verfahren zur Behandlung der Schizophrenie sowie Mittel zur Verwendung in diesem Verfahren
PCT/EP1999/007320 WO2000023077A1 (fr) 1998-10-16 1999-10-02 Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede

Publications (1)

Publication Number Publication Date
EP1121126A1 true EP1121126A1 (fr) 2001-08-08

Family

ID=7884666

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99948923A Ceased EP1121126A1 (fr) 1998-10-16 1999-10-02 Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede

Country Status (10)

Country Link
EP (1) EP1121126A1 (fr)
JP (1) JP2002527478A (fr)
KR (1) KR20010080135A (fr)
CN (1) CN1323210A (fr)
AR (1) AR020815A1 (fr)
AU (1) AU6199299A (fr)
BR (1) BR9914570A (fr)
CA (1) CA2341855A1 (fr)
DE (1) DE19847715A1 (fr)
WO (1) WO2000023077A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
KR20060120156A (ko) * 2003-10-28 2006-11-24 알자 코포레이션 담배의 이용빈도를 감소시키기 위한 방법 및 장치
IL177071A0 (en) * 2005-08-01 2006-12-10 Nitto Denko Corp Method of preparing a nicotine transdermal preparation
WO2012154710A1 (fr) * 2011-05-09 2012-11-15 Envivo Pharmaceuticals, Inc. Traitement de troubles cognitifs par certains agonistes du récepteur nicotinique alpha-7 en combinaison avec la nicotine
CZ309812B6 (cs) * 2021-05-25 2023-11-01 Consumer Brands International s.r.o Směs pro výrobu nikotinových sáčků a způsob její výroby

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4915950A (en) * 1988-02-12 1990-04-10 Cygnus Research Corporation Printed transdermal drug delivery device
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
US5776956A (en) * 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0023077A1 *

Also Published As

Publication number Publication date
AR020815A1 (es) 2002-05-29
KR20010080135A (ko) 2001-08-22
BR9914570A (pt) 2001-07-03
CA2341855A1 (fr) 2000-04-27
CN1323210A (zh) 2001-11-21
AU6199299A (en) 2000-05-08
WO2000023077A1 (fr) 2000-04-27
DE19847715A1 (de) 2000-04-20
JP2002527478A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
DE60100595T2 (de) Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson
DE602004012403T2 (de) Zusammensetzungen zur beeinflussung des gewichtsverlusts
EP1696904B1 (fr) Utilisation de rotigotine pour traiter ou prevenir la perte des neurones dopaminergiques
DE60019436T2 (de) Verwendung von nikotin oder derivaten davon und l-dopa in einem medikament zur behandlung von neurologischen erkrankungen, insbesondere der parkinson-erkrankung
DE60100994T2 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DE20122843U1 (de) Fentanyl Zusammensetzung zur nasalen Anwendung
DE69926804T2 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
DE10220230A1 (de) Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
EP0697869B1 (fr) Systemes therapeutiques transdermiques pour l'administration d'agonistes de la serotonine
DE60111025T2 (de) Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose
WO2008119097A1 (fr) Agent pharmaceutique contre les démangeaisons et la douleur
EP1850836B1 (fr) Traitement medicamenteux combine
DE4328217C2 (de) Therapeutisches System zur Behandlung der Psoriasis
DE69634662T2 (de) Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester
EP1121126A1 (fr) Procede pour traiter la schizophrenie et substance utilisee dans le cadre de ce procede
DE19850517B4 (de) Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
EP1656112B1 (fr) Formules orales de la galanthamine et leurs applications
WO2006030030A2 (fr) Systeme pour l'administration transdermique sequentielle de substances a action systemique
AT402691B (de) Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
DE69631597T2 (de) Kombination aus einem beta rezeptorblocker und einem opioid
DE60027282T2 (de) Verwendung von l-threo-methylphenidate zur Herstellung eines Medikaments für die Behandlung von Depression
EP1408968B1 (fr) Sevrage a la nicotine adapte aux recepteurs par une combinaison d'atropine, scopolamine, clonidine
EP1383503B1 (fr) Utilisation de desoxypeganine pour traiter des symptomes pathologiques du systeme nerveux central resultant d'intoxications avec des substances psychotropes
EP1725229B1 (fr) Utilisation de desoxypeganine pour traiter des psychoses schizophrenes
DE60036640T2 (de) Mittel zum stimulieren von körpergewichtzunahme, verfahren und produkt

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011106

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20030517